Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Migraine Headaches

Interventions

DRUG

ELS-M11

One dose of 5% ELS-M11 over 3 bilateral applications.

DRUG

Placebo

One dose of matching placebo over 3 bilateral applications.

Trial Locations (2)

Coastal Carolina Research Center, Charleston

Michigan Head Pain and Neurological Institute, Ann Arbor